Trial
NCT01870609
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Verastem, Inc.
Collaborators
—
Condition
Malignant Pleural Mesothelioma
Intervention
defactinib (VS-6063)
Why stopped
Interim analysis-DSMB stated good safety profile but lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-30